Patients with Alzheimer’s disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease


Abstract

Objectives—To describe the clinical presentation of patients with Alzheimer’s disease (AD) or dementia with Lewy bodies (DLB) who were suspected of having Creutzfeldt-Jakob disease (CJD) and to investigate whether current clinical diagnostic criteria cover these atypical forms of AD and DLB.

Methods—Brains from necropsy were examined for the diagnosis of CJD at the German reference centre for spongiform encephalopathies. Symptoms and signs in patients with suspected CJD in whom necropsy showed AD (n=19) or DLB (n=12) were analysed. Their data were compared with a group of patients with CJD (n=25) to determine overlapping and discriminating clinical features. All patients were classified according to clinical diagnostic criteria for CJD, AD, and DLB.

Results—Demented patients were suspected of having CJD if disease was rapidly progressing and/or focal neurological signs appeared and/or an EEG showed sharp wave complexes. Myoclonus and limb rigidity were the most common neurological signs in all three dementias. DLB was not suspected in any patient, although patients with DLB showed parkinsonism (58%) and fluctuations (58%). Periodic sharp wave complexes (PSWCs) in the EEG typical of CJD were found in five patients with AD and one patient with DLB. 14–3–3 Protein in CSF was detected in 20 patients with CJD, in two patients with AD, but not in any patient with DLB. Although most patients with DLB or AD met the clinical criteria for their respective diagnosis (74% and 90%), they also fulfilled criteria for CJD (42% and 58%).

Conclusions—In patients with rapidly progressive dementia and focal neurological signs, CJD should be the first line diagnosis. Facing the triad dementia, myoclonus, and rigidity, AD should be considered if the disease course is longer and DLB is the differential diagnosis if parkinsonism or fluctuations are present. Findings on EEG or CSF typical of CJD do not exclude AD or DLB.

Keywords: Creutzfeldt-Jakob disease; dementia with Lewy bodies; Alzheimer’s disease; diagnosis

Creutzfeldt-Jakob disease (CJD), Alzheimer’s disease (AD), and dementia with Lewy bodies (DLB) are human neurodegenerative disorders presenting with dementia as their principal sign. All three are of unknown origin and have a fatal outcome. Whereas CJD is a rare disease with an incidence of around one case/million/year AD and DLB are the most common causes of dementia in elderly people.

In most cases, patients with CJD have a rapidly progressive disease course and periodic sharp wave complexes (PSWCs) in the EEG. They usually develop neurological signs such as gait disturbances or myoclonus. Most patients become bedridden and die after a median disease duration of 7 months. Generall, AD is of slow course (duration of illness 7–8 years) and neurological signs appear only in late stages of the disease. DLB was recently defined as a separate disease entity with the characteristics of dementia, parkinsonism, visual hallucinations, fluctuations in cognitive impairment, and neuroleptic hypersensitivity. Life expectancy in DLB of 5–8 years is shorter than in AD.

Studies on patients with DLB whose diagnoses were confirmed by necropsy focus on the clinical differentiation of DLB and AD or DLB and Parkinson’s disease. There have included only a few patients. There are case reports of necropsy confirmed patients with AD and patients with DLB in whom CJD had been clinically suspected, but no systematic study has yet been undertaken to differentiate those patients with a rapidly progressive disease course.

In our study we describe a larger number of patients suspected clinically of having CJD but in whom AD or DLB was shown at postmortem examination. Frequency of clinical signs and symptoms and the results of technical investigations are reported. Reliability of current clinical diagnostic criteria for CJD, DLB, and AD is evaluated, and a diagnostic pattern is proposed to facilitate clinical differential diagnosis.

Materials and methods

Patients

Since 1993 brains from necropsies have been sent to the German reference centre for spongiform encephalopathies for the diagnosis of Creutzfeldt-Jakob disease or genetic prion disease. Most patients necropsied were examined as suspected CJD cases during their lifetime by a study physician of the German CJD surveillance unit.
We collected clinical data from patients in whom CJD was ruled out by neuropathology, and in whom AD or DLB were confirmed.

The control group of 25 patients with definite sporadic CJD was recruited from patients consecutively referred to the CJD surveillance unit in the same period as the patients with AD and those with DLB. Recruitment of patients with CJD ceased as soon as a representative group of patients was achieved that corresponded in clinical signs and symptoms to our previous findings. Patients with genetic or iatrogenic prion disease were excluded.

ANALYSIS OF CLINICAL DATA
Medical records of all patients were studied retrospectively. Each patient’s chart was analysed with a standardised checklist, which contained the following items:

(1) Reason for sending in material for prion disease analysis.

(2) Signs and symptoms typical for CJD were rated according to modified Masters criteria. Extrapyramidal signs were subdivided into limb rigidity, parkinsonism, and dystonic, choreatic, athetoid or ballistic movements. Visual disturbances included deteriorated or blurred vision, visual field restriction, and disturbed perception of structures and colours. Visual hallucinations were rated separately.

Clinical features of AD were rated according to NINCDS-ADRDA criteria. Clinical features of DLB were noted according to McKeith et al.'s criteria.

(3) Technical investigations: All EEGs were initially reviewed by one of us (SP). The EEGs were additionally reviewed without knowledge of clinical information by a second observer (BJS). "CJD typical EEG" was diagnosed in EEG tracings fulfilling Steinhoff's criteria. Testing for protein 14–3–3 and neuron specific enolase (NSE) in CSF was performed as previously described. A cut off for CJD was defined as NSE concentration>35 ng/ml in CSF.

CLINICAL CLASSIFICATION OF PATIENTS
Using the results from the above checklist, patients were classified according to international diagnostic criteria for CJD, AD, and DLB. Each patient was clinically classified for all three dementia entities. The categories "possible", "probable", and "other disease" (not fulfilling the criteria) were used to express the degree of certainty in the clinical diagnosis.

NEUROPATHOLOGICAL EVALUATION
Brains were fixed in 10% formalin for at least 14 days. Representative blocks were cut, decontaminated for 1 hour in concentrated formic acid, and embedded in paraffin. Whenever possible recommended regions according to the consensus criteria for diagnosing AD and DLB were used. Paraffin sections (2 µm) were stained with haematoxylin and cosin and with Bielschowsky methods. Immunocytochemistry was performed with monoclonal antibodies against a synthetic peptide corresponding to 138–152 of the human prion protein (Gö138, Göttingen, Germany), β-amyloid (ǐbo4, Boehringer Mannheim, Germany), phosphorylated tau (AT8, Innogenetics, Ghent, Belgium), and a polyclonal antiserum against α-synuclein (Q698, MPI Göttingen, Germany).

NEUROPATHOLOGICAL DIAGNOSTIC CRITERIA
Prion diseases
The definite diagnosis of prion disease is based on the detection of prion protein (PrP) deposits using PrP immunocytochemistry.

Alzheimer’s disease
Alzheimer’s disease related pathology was classified using the CERAD pathological criteria based on semiquantitative analysis of neuritic plaques (Bielschowsky stain, α-synuclein immunostain) as well as the Braak and Braak classification based on the distribution of neurofibrillary tangles and neuritic threads (Bielschowsky stain, AT8 immunostain).

The 19 cases of AD were subclassified as CERAD C/Braak and Braak stage V-VI (n=14) and CERAD B/Braak and Braak stage III-IV (n=5).

Dementia with Lewy bodies
Distribution and frequency of Lewy bodies were evaluated according to the consensus criteria for diagnosing DLB. The number of LBs were counted in the brain regions determined in the protocol (α-synuclein immunostain) and converted into scores from 0 (no LBs), 1 (1–4 LBs), and 2 (>5 LBs) for each area. Based on the total score, cases were divided into three subtypes: brainstem dominant, limbic, and neocortical.

The 12 cases of DLB examined here were subclassified as neocortical (n=10) and limbic (n=2) subtypes.

GENETIC ANALYSIS
A screening of mutations in the prion protein gene (PRNP) was performed in 20 patients with CJD using single strand conformation polymorphism (SSCP) analysis or direct DNA sequence analysis, as described previously. No mutations in PRNP were detected in the patients included in this study.

Results
PATIENTS
From June 1993 to June 1997 brain tissue from 413 suspected cases of CJD was examined in the German reference centre for spongiform encephalopathies. In 309 cases, sporadic CJD or genetic prion disease was confirmed; in 104 cases prion disease was ruled out. In these 104 cases, Alzheimer’s disease was most often diagnosed (28 cases), followed by dementia with Lewy bodies (14 cases).

Nine patients with AD and two patients with DLB were excluded from the analysis because details of clinical examination were absent. Nineteen patients with AD and 12 patients with DLB were included in this study. Among these necropsy confirmed patients, 14 with AD and five with DLB were seen prospectively by a
### Table 1 Clinical signs and symptoms at onset of disease

<table>
<thead>
<tr>
<th>Sign/symptom</th>
<th>CJD patients</th>
<th>AD patients</th>
<th>DLB patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dementia only</td>
<td>7 (28)</td>
<td>12 (63)</td>
<td>5 (42)</td>
</tr>
<tr>
<td>Dementia/neurological signs/symptoms</td>
<td>4 (16)</td>
<td>3 (16)†</td>
<td>2 (17)†</td>
</tr>
<tr>
<td>Dementia (total)</td>
<td>11 (44)</td>
<td>15 (79)</td>
<td>7 (58)</td>
</tr>
<tr>
<td>Gait disturbances</td>
<td>7 (28)</td>
<td>1 (5)</td>
<td>—</td>
</tr>
<tr>
<td>Visual disturbances</td>
<td>7 (27)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Confusion</td>
<td>4 (16)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Vertigo</td>
<td>4 (15)</td>
<td>1 (5)</td>
<td>—</td>
</tr>
<tr>
<td>Aphasia</td>
<td>2 (8)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Behavioural changes</td>
<td>2 (8)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Dyskinesia</td>
<td>1 (4)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>1 (4)</td>
<td>1 (5)</td>
<td>—</td>
</tr>
<tr>
<td>Parkinsonism</td>
<td>2 (8)</td>
<td>—</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Limb paresis</td>
<td>1 (4)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Myoclonus</td>
<td>—</td>
<td>1 (5)</td>
<td>—</td>
</tr>
<tr>
<td>Epileptic seizures</td>
<td>—</td>
<td>3 (16)</td>
<td>—</td>
</tr>
<tr>
<td>Delusion</td>
<td>—</td>
<td>1 (8)</td>
<td>—</td>
</tr>
<tr>
<td>Aggressive behaviour</td>
<td>—</td>
<td>1 (8)</td>
<td>—</td>
</tr>
<tr>
<td>No data</td>
<td>—</td>
<td>—</td>
<td>3 (25)</td>
</tr>
</tbody>
</table>

*Multiple mentioning possible.
†Neurological signs in CJD patients were dystonia, gait disturbances, visual disturbances, and confusion; in AD patients they were myoclonus, epileptic seizures or gait disturbances; in DLB patients they were parkinsonism or visual hallucinations.

— Signs not noted.

A member of the epidemiological CJD surveillance unit. The medical records were obtained from the remaining patients.

Twenty five patients with confirmed CJD served as a control group.

### Table 2 Summary of clinical signs and symptoms during course of disease

<table>
<thead>
<tr>
<th>Sign/symptom</th>
<th>CJD patients</th>
<th>AD patients</th>
<th>DLB patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dementia</td>
<td>25 (100)</td>
<td>19 (100)</td>
<td>12 (100)</td>
</tr>
<tr>
<td>Myoclonus</td>
<td>22 (88)</td>
<td>11 (58)</td>
<td>9 (75)</td>
</tr>
<tr>
<td>Extrapyramidal signs</td>
<td>21 (84)</td>
<td>10 (53)</td>
<td>11 (92)</td>
</tr>
<tr>
<td>Limb rigidity</td>
<td>17 (68)</td>
<td>10 (53)</td>
<td>11 (92)</td>
</tr>
<tr>
<td>Parkinsonism</td>
<td>2 (8)</td>
<td>—</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Choreatic/athetoid/ballistic/dystonic signs</td>
<td>10 (40)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Pyramidal signs</td>
<td>19 (76)</td>
<td>6 (32)</td>
<td>2 (17)</td>
</tr>
<tr>
<td>Cerebellar signs</td>
<td>23 (92)</td>
<td>7 (37)</td>
<td>—</td>
</tr>
<tr>
<td>Gait or postural ataxia</td>
<td>20 (80)</td>
<td>3 (16)</td>
<td>—</td>
</tr>
<tr>
<td>Limb ataxia</td>
<td>15 (60)</td>
<td>5 (26)</td>
<td>—</td>
</tr>
<tr>
<td>Visual disturbances*</td>
<td>12 (44)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Akinetik mutism</td>
<td>16 (64)</td>
<td>4 (21)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Fluctuations</td>
<td>—</td>
<td>1 (5)</td>
<td>7 (58)</td>
</tr>
<tr>
<td>Visual hallucinations</td>
<td>9 (36)</td>
<td>2 (11)</td>
<td>7 (58)</td>
</tr>
<tr>
<td>Recurrent falls</td>
<td>4 (16)</td>
<td>6 (32)</td>
<td>6 (50)</td>
</tr>
<tr>
<td>Neuroleptic hypersensitivity</td>
<td>—</td>
<td>—</td>
<td>1 (8)</td>
</tr>
<tr>
<td>Dementia</td>
<td>3 (12)</td>
<td>5 (26)</td>
<td>9 (75)</td>
</tr>
</tbody>
</table>

*Visual disturbances included deterioration of vision (n=2), blurred vision (n=3), visual field restriction (n=4), disturbed perception of structures and colours (n=3), and double vision (n=3).
†Neuroleptic medication was received by six AD patients, nine DLB patients, and one CJD patient without notice of hypersensitivity by treating physician.

— Signs not noted.

### Table 3 Results of technical investigations

<table>
<thead>
<tr>
<th>Test</th>
<th>CJD patients (n=25)</th>
<th>AD patients (n=19)</th>
<th>DLB patients (n=12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSWCs in EEG</td>
<td>56% (14/25)</td>
<td>31% (5/16)</td>
<td>8% (1/12)</td>
</tr>
<tr>
<td>Protein 14-3-3 in CSF</td>
<td>87% (20/23)</td>
<td>18% (2/11)</td>
<td>0% (0/5)</td>
</tr>
<tr>
<td>Median NSE value in CSF (ng/ml)</td>
<td>62.5 (range: 15-210)</td>
<td>13 (range: 6-120)</td>
<td>16 (range: 6-22)</td>
</tr>
<tr>
<td>NSE raised in CSF</td>
<td>73% (16/22)</td>
<td>29% (2/7)</td>
<td>0% (0/5)</td>
</tr>
</tbody>
</table>

PSWCs=periodic sharp wave complexes; NSE = neuron specific enolase.

The median duration of illness varied from 4 months (range 2–24 months) in patients with CJD to 18.5 months (range 1–60 months) in patients with DLB and 24 months (range 3–108 months) in patients with AD. A patient with AD was suspected of having CJD after 9 years of disease course when he developed rigidity and myoclonus.

### REASONS FOR SUBMITTING BRAIN TISSUE FOR PRION DISEASE ANALYSIS

#### Patients with CJD (n=25)

In 20 patients the primary clinical diagnosis was CJD, the remaining five patients were referred as patients with suspected CJD with other differential diagnoses.

#### Patients with AD (n=19)

Nine patients had rapidly progressive dementia with or without focal neurological signs and the EEG showed sharp wave complexes; therefore CJD was clinically suspected. “Probable” CJD was diagnosed in five of these patients with AD as sharp wave complexes fulfilled criteria for periodicity.1 In 10 further patients CJD was considered in the differential diagnosis as the disease course was very rapid.

#### Patients with DLB (n=12)

One patient’s clinical diagnosis by the notifying hospital was CJD, because of rapidly progressing illness with dementia, parkinsonian syndromes, and myoclonus, but without specific EEG findings. In the remaining patients CJD was suspected because of rapid progression of disease, and/or the development of myoclonus. In two of these patients, EEG showed sharp wave complexes, one of those fulfilled criteria for periodicity; therefore in this patient CJD was clinically “probable”.

### CLINICAL SIGNS AND SYMPTOMS AT ONSET OF DISEASE

The details are listed in table 1. Dementia was the first sign of disease in most patients with AD and those with DLB and in 44% of patients with CJD. Whereas patients with AD or with DLB often had dementia only, in many patients with CJD, dementia was accompanied by neurological signs or symptoms, or neurological signs preceded dementia.

### CLINICAL SIGNS AND SYMPTOMS DURING THE COURSE OF DISEASE

All patients developed dementia. Myoclonus and extrapyramidal signs were especially common in patients with CJD and patients with DLB (>80% and >70% respectively) and in more than 50% of patients with AD (see table 2 for details). Extrapyramidal signs in patients with AD and with DLB were restricted to limb rigidity (>50% respectively) and parkinsonism (58% in patients with DLB, 8% in CJD, and 11% in AD). Patients with CJD additionally showed hyperkinetic signs (40%). Nearly all patients with CJD and 37% of patients with AD had cerebellar signs, not noted in DLB. Visual disturbances such as loss or deterioration...
tion of vision, visual field restriction, or disturbed perception of colours and structures were exclusively found in CJD (44% of patients).

Signs typical of DLB such as fluctuations of cognitive impairment were found in 58% of patients with DLB, but only in one patient with AD and no patients with CJD. Visual hallucinations were most common in DLB (58%), but were also present in CJD (36%) and AD (11%). Referring physicians did not report neuroleptic hypersensitivity in any patient, including nine patients with DLB (75%), six patients with AD (32%), and one patient with CJD (4%) who had received neuroleptic medication.

Figure 1  CJD typical periodic sharp wave complexes in EEGs from (A) a histologically proved AD patient, aged 76 years after 4 months of disease (EEG curves by courtesy of Dr E Banzhaf). (B) A histologically proved patient with DLB, aged 77 years, after 36 months of disease (EEG curves by courtesy of Professor R Benecke).
Patients with definite AD
In 16% of patients with AD the diagnosis of “possible” CJD was made, in 26% “probable” CJD was diagnosed clinically; 74% of patients with AD fulfilled clinical criteria of “probable” AD; one patient with AD (5%) met the criteria for “probable” DLB (dementia, fluctuations, parkinsonism, and visual hallucinations); and one patient met the criteria for “possible” DLB (dementia and visual hallucinations). In another patient with AD, dementia had preceded the development of parkinsonism by 9 years, so that in this case parkinsonism was not rated for the diagnosis of DLB.

Patients with definite DLB
”Possible” CJD was diagnosed in 50% of patients with DLB, but only one patient with DLB had CJD typical PSWCs in EEG recordings and was therefore clinically “probable” CJD; 58% of patients with DLB met criteria for “probable” AD; 84% of patients with DLB fulfilled clinical criteria for “possible” or “probable” DLB (42% each, fig 2).

Discussion
Our series is the first to describe clinical findings on a large number of patients erroneously suspected of having Creutzfeldt-Jakob disease, who were histologically proved to have Alzheimer’s disease or dementia with Lewy bodies. We are aware of only three comparable series26–28 that report necropsy results of suspect patients with CJD who had other final diagnoses. Detailed clinical information was not given in these series. In all studies, AD was the most frequent alternative diagnosis; DLB was not mentioned, as it was only recently defined as a separate diagnostic entity.

As shown in clinicopathological studies,7 26–29 clinical diagnosis in patients with dementia has become increasingly accurate, ranging from a specificity of 95% in CJD28 and 90%-97% in DLB7 to 79%29 in AD. Thus, patients with typical clinical presentation seem to be sufficiently covered by current diagnostic criteria. However, differential diagnosis is a major challenge in atypical cases, such as patients with rapidly progressive AD or DLB or patients with slowly progressive CJD.

In our study, CJD was suspected in patients with AD or DLB if the disease course was rapid or patients developed focal neurological signs, especially myoclonus, or if EEG was considered to point to CJD.

In most patients with AD or with DLB, dementia was present already at the onset of disease, corresponding to the literature.4 17 By contrast, patients with CJD additionally had focal neurological signs such as gait or visual disturbances. During the course of disease dementia, myoclonus, and limb rigidity were the overlapping features of the three patient groups. Due to selection of “CJD-like” cases myoclonus was more common in DLB (75%) and AD (58%) than usually reported (19% in DLB26 and 10% in AD25). In accordance with the literature,10 extrapyramidal signs were the cardinal features in patients with DLB. Parkinsonism was rarely found in patients with AD.

CLINICAL CLASSIFICATION OF PATIENTS

Patients with definite CJD
”Probable” CJD was diagnosed in 84% of patients with CJD. In 16% (4/25) of patients with CJD technical investigations were not typical for CJD; therefore CJD was “possible”. According to the diagnostic criteria for AD the diagnosis of AD was “probable” in 24% of cases. Sixteen per cent of patients with CJD fulfilled clinical criteria for “possible” DLB (dementia and visual hallucinations or parkinsonism).
and those with CJD, but was present in 58% of patients with DLB. Although described also in 6% of patients with DLB in the literature, we found choreoathetoid or dystonic movements exclusively in patients with CJD. Clinical signs particularly common in CJD were ataxia and visual disturbances. A differentiation of visual disturbances from visual hallucinations was especially helpful. Although visual disturbances were found exclusively in CJD, visual hallucinations were present in all three dementia syndromes which show predominantly visual impairments, this should be further investigated.

Although the clinical course was more rapid and myoclonus was more common than generally, our patients with DLB showed the cardinal features of DLB (fig 3). Neuroleptic hypersensitivity, a complication in DLB, was not described in any of the patients by the treating physicians. Looking for the clinical details in our patients with DLB, nine of them received neuroleptic medication (median 2 months before death). In six of them, further clinical deterioration and death (median 1 month later) could be consistent with neuroleptic hypersensitivity as described in the literature. In three patients with DLB, no hypersensitivity to neuroleptic drugs was found, even with hindsight. Both factors, the lack of hypersensitivity in some patients and no clear correlation of clinical deterioration with administration of neuroleptic drugs, could have contributed to missing the clinical diagnosis of DLB.

Using the diagnostic criteria for PSWCs proposed by Steinhoff et al, we found EEGs typical of CJD in 56% of patients with CJD, which is slightly less than previously reported. In five patients with AD and one patient with DLB, EEG was indistinguishable from typical CJD findings (fig 1A and B). In four additional patients with AD and two patients with DLB, EEG was considered by notifying hospitals to be compatible with CJD, but these EEGs did not correspond to the established criteria. The high frequency of false positive EEGs is most probably due to study design: demented patients are often referred due to “CJD-like” EEG. In the literature there are reports on periodic sharp wave complexes in single cases of AD and in two cases of DLB. “Pseudoperiodicity” in EEG is reported to be more often found in patients with DLB.

Analysis of CSF yielded false positive results for 14–3–3 protein and NSE in one patient with AD and false positive 14–3–3 with normal NSE in another patient with AD. An explanation for the first patient could be an epileptic seizure 4 days before taking the CSF. In the five patients with DLB tested, 14–3–3 was negative and NSE was within the normal range. Negative findings for protein 14–3–3 and NSE in the CSF have also been found in five patients with DLB in another laboratory (Aksamit AJ, personal communication and Aksamit et al).

According to Parchi et al, in sporadic CJD disease different subtypes exist. As described in detail by Zerr et al, the typical clinical phenotype with rapidly progressive dementia, myoclonus and typical EEG and CSF findings is present in about 70% of patients with CJD. In 10% of cases of CJD, disease duration is longer and patients often show extrapyramidal signs (MV2 subtype). In these patients EEG does not show CJD typical PSWCs and testing for protein 14–3–3 yields inconsistent results. The patients with MV2 and CJD could thus be missed or mistaken as a non-CJD neurodegenerative disorder, especially DLB. By contrast with AD or DLB, the patients with MV2 and CJD often exhibit ataxia as well as extrapyramidal features. Magnetic resonance imaging showing CJD typical findings in patients with MV2 could also help in the differential diagnosis. Due to lack of material no MR scans were described in this study.

Testing overlap in classification criteria (fig 2), we showed that “probable” CJD was misdiagnosed in six patients with the combination of limb rigidity, myoclonus, and false positive EEGs or CSF data. Classification of all patients according to AD criteria showed also that six patients with CJD and seven patients with DLB met criteria for “probable” AD. Comparable series on patients with DLB reported clinical criteria for “probable” AD in 15% and for “possible” AD in 50% of cases. In our study, DLB criteria specifically identified 84% of patients with DLB and falsely classified 16% of patients with CJD and 11% of patients with AD as having DLB.

Although our patients with DLB showed the major clinical signs of DLB (table 2), this disease was not mentioned as a clinical diagnosis in any of our patients. This accords with general findings that DLB escapes diagnosis in up to 66% of cases during a lifetime, probably because it is still quite unknown to the clinicians and specific technical examinations for DLB are lacking.

In summary, in patients with rapidly progressive dementia and focal neurological signs, CJD should be the primary diagnosis, especially if EEG shows periodic sharp wave complexes or if the 14–3–3 protein is detectable in CSF. Ataxia, visual disturbances, and hyperkinetic limb movements are strong
Figure 4 Diagnostic pattern in the differential diagnosis of patients with the triad dementia, myoclonus, and rigidity.

This study was supported by a grant from the Bundesministe-
rum for Health, Bonn, Germany, to HAK and to SP.

1 Poser S, Zerr I, Schulz-Schaeffer W, et al. Creutzfeldt-
Jakob-Krankheit. Eine Sphinx der heutigen Neurobiologie.

1449–58.

3 Hafner H. Epidemiology of Alzheimer’s disease. In: Maurer
et al. eds. Epidemiology, neuropathology, neurochemistry and

of Alzheimer’s disease: report of the NINCDS-
ADRDA work group under the auspices of the Department of
Health and Human Services task force of Alzheimer’s disease.

5 McKhann G, Galasko D, Kauk M, et al. Consensus guide-
lines for the clinical and pathological diagnosis of dementia
with Lewy bodies (DLB): report of the consortium on

6 Heyman A, Fillenbaum GG, Gearing M, et al. Comparison of
Lewy body variant of Alzheimer’s disease with pure

7 McKeith IG, Fairbairn AP, Bottrell RA, et al. An evalua-
tion of the predictive validity and inter-rater reliability
of the clinical diagnostic criteria for senile dementia of

8 Litvan MD, MacIntyre A, Goetz CG, et al. Accuracy of the
clinical diagnosis of Lewy body disease, Parkinson disease
dementia and dementia with Lewy bodies. Arch Neurol 1998;55:969–
76.

9 Louis ED, Klatsky LA, Liu Y, et al. Comparison of extrapy-
ramidal features in 31 pathologically confirmed cases of
diffuse Lewy body disease and 34 pathologically confirmed

10 Fiden AJ, Townsend J. Myoclonus in Alzheimer disease.

11 Katz PR, Chukwujb KJQ. Dementia, myoclonus and EEG
findings typical of Creutzfeldt-Jakob disease in a patient

12 Watson CP. Clinical similarity of Alzheimer and

13 Burkhart FR, Fille C, Kleinschmidt-DeMasters BK, et al. Diffuse

genetics of human prion diseases in Germany. Hum Genet

15 Masters CL, Harris J, Gajdusek DC, et al. Creutzfeldt-
Jakob disease: patterns of worldwide occurrence and the
significance of familial and sporadic clustering. Ann Neurol

protein in the cerebrospinal fluid supports the diagnosis of

classification criterion for the diagnosis of Creutzfeldt-Jakob

18 McKeith IG, Fairbairn AP, Perry RH, et al. Neurological
hypersensitivity in patients with senile dementia of Lewy

and reliability of periodic sharp wave complexes in Creutzfeldt-

20 World Health Organization. Human transmissible spong-
iform encephalopathies. Weekly Epidemiological Record 1986:

21 Brown P, Gajdusek DC. A simple and effective method for
inactivating virus infectivity in formalin-fixed tissue sam-
plies from patients with Creutzfeldt-Jakob disease. Neuro-

22 Hyman BT, Trojanowsky JQ. Editorial recommendations for
the postmortem diagnosis of Alzheimer’s disease from the
National Institute on Aging and the Reagan Institute
Working Group on the diagnostic criteria for the neu-
ropathological assessment of Alzheimer’s disease. J Neu-

criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol

24 Mura SH, Herman AA, McKend D, et al. The Consortium
to Establish a Registry for Alzheimer’s disease (CERAD).
Part II. Standardization of the neuropathological assessment

25 Braak H, Braak E. Neuropathological staging of Alzheimer-

sporadic encephalopathy: the National Institutes of
Health series of 300 cases of experimentally transmitted

27 Will RG, Matthews WB. A retrospective study of Creutzfeldt-
Jakob disease in England and Wales 1928–90: I. clinical

the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 1999;
122:2345–54.

29 Lopez OL, Lütarn I, Catt KE, et al. Accuracy of four clinical
diagnostic criteria for the diagnosis of neurodegenerative

30 Hauser WA, Morris ML, Heston LL, et al. Seizures and
myoclonus in Alzheimer’s disease. Neurology 1986;36:
1226–30.

31 Pantel J, Schröder J. Posterior cortical atrophy: ein neues
Demenzsyndrom oder Sonderform des Morbus Alzhe-

32 Yamamoto T, Imaji T. A case of diffuse Lewy body disease
and Alzheimer’s disease with periodic eye movements and

33 Crystal HA, Dickson DW, Lizardi JI, et al. Antemortem
diagnosis of diffuse Lewy body disease. Neurology 1990:40:
1523–58.

34 Akasami AJ, Homburger HA, Preissner CM. Creutzfeldt-
Jakob disease: correlation with spinal fluid NSE and

Creutzfeldt-Jakob disease based on molecular and phento-
typic analysis of 300 subjects. Acta Neuropathol 1999:46:
224–33.

diagnosis in Creutzfeldt-Jakob disease: identification of

range and MRI in Creutzfeldt-Jakob disease with hereditary
genetics at codon 129 and prion protein type 2. J Neurol
1998;245:26–33.

imaging (MRI) in the clinical diagnosis of Creutzfeldt-
Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease


J Neurol Neurosurg Psychiatry 2001 71: 33-39
doi: 10.1136/jnnp.71.1.33

Updated information and services can be found at:
http://jnnp.bmj.com/content/71/1/33

These include:

References
This article cites 35 articles, 17 of which you can access for free at:
http://jnnp.bmj.com/content/71/1/33#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Dementia (1020)
Memory disorders (psychiatry) (1390)
Infection (neurology) (494)
Parkinson's disease (690)
Variant Creutzfeldt-Jakob Disease (71)
Drugs: CNS (not psychiatric) (1945)
Psychiatry of old age (338)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/